Treatment of pathologies which escape the immune response, using optimised antibodies

摘要

The invention relates to the use of optimised human or humanised chimeric monoclonal antibodies which are produced cell lines, said antibodies having a strong affinity for receptor CD16 of the effector cells of the immune system and being able to induce the secretion of cytokines and interleukins, in particular 1' IFN? or 1' IL2, for the treatment of pathologies for which the target cells only express a low antigenic density and in which the effector cells can only be recruited in small quantities.